معرفی
Dr. Mark Sleeman is an Adjunct Professor in the Department of Comparative Medicine at Yale University and serves as Head of Metabolic Research at Regeneron Pharmaceuticals in Tarrytown, New York. His research focuses on metabolic processes, insulin resistance, obesity, and the role of gut hormones like ghrelin and PYY in regulating metabolic events. He employs genetically modified animal models to study food intake, body weight control, and long-term metabolic regulation, including bone and mineral metabolism.
Dr. Sleeman holds a PhD in neurobiology from Monash University (Australia) and completed a Juvenile Diabetes and Ruth Kirschstein Endocrine Fellowship at the University of Massachusetts. His work has led to seminal contributions in insulin signaling, diabetes mechanisms, and the expansion of research on ghrelin. He has published extensively in high-impact journals such as Nature Medicine, Cell Metabolism, and PNAS.
Key awards include the Juvenile Diabetes and Ruth Kirschstein Endocrine Fellowship. His leadership spans both academic and industry settings, bridging discovery research and therapeutic development in metabolic diseases. Collaborations with institutions like Yale and Regeneron highlight his interdisciplinary approach to advancing metabolic science.
His recent studies address NAFLD mechanisms, cytokine signaling pathways, and the divergent roles of genes like MARC1 in human and mouse models. These efforts aim to clarify complex metabolic interactions and inform therapeutic strategies for obesity, diabetes, and related conditions.
